Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cytokine storm

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    11 result(s) found for: Cytokine storm. Displaying page 1 of 1.
    EudraCT Number: 2020-001825-29 Sponsor Protocol Number: ANA-COVID-GEAS Start Date*: 2020-04-28
    Sponsor Name:NAVARRABIOMED - FUNDACIÓN MIGUEL SERVET
    Full Title: CLINICAL TRIAL OF THE USE OF ANAKINRA (ANTI IL-1) IN CYTOKINE STORM SYNDROME (CSS) SECONDARY TO COVID-19
    Medical condition: Hyperinflammation and respiratory distress in patients with SARS- CoV-2
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-001662-11 Sponsor Protocol Number: CINC424J12301 Start Date*: 2020-05-05
    Sponsor Name:Novartis Pharma AG
    Full Title: Phase 3 randomized, double-blind, placebo-controlled, multi-center study to assess the efficacy and safety of ruxolitinib in patients with COVID-19 associated cytokine storm (RUXCOVID)
    Medical condition: COVID-19 associated cytokine storm
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) FR (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-001732-10 Sponsor Protocol Number: KKS-278 Start Date*: 2020-05-28
    Sponsor Name:Philipps-Universität Marburg
    Full Title: Ruxolitinib for treatment of Covid-19 induced lung injury ARDS (RuXoCoil) A single-arm, open-label, proof of concept study
    Medical condition: SARS-CoV-2 induced ARDS
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-001558-23 Sponsor Protocol Number: COFID19-AIFA17/2020 Start Date*: 2020-04-09
    Sponsor Name:ASUR (Azienda Sanitaria Unica Regionale) Marche
    Full Title: Hydroxychloroquine sulfate early administration in symptomatic out of hospital COVID-19 positive patients. Hydro-Stop-COVID19 Trial
    Medical condition: Emerging disease (COVID-19) due to a novel coronavirus (named SARS-CoV-2 latter) started in Wuhan, China and rapidly spread in China and outside and has been declared pandemic by WHO on March 12th ...
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004862 10063099 Viral syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-001255-40 Sponsor Protocol Number: STRIKE-SARS-CoV2 Start Date*: 2020-04-16
    Sponsor Name:Clínica Universidad de Navarra/Universidad de Navarra
    Full Title: Sarilumab Treatment In cytoKinE storm caused by infection with COVID-19.
    Medical condition: Severe pneumonia caused by infection with SARS CoV 2.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10051905 Coronavirus infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2020-001500-41 Sponsor Protocol Number: COV-AID Start Date*: 2020-04-03
    Sponsor Name:University Hospital Ghent
    Full Title: A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard ...
    Medical condition: COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2021-003240-25 Sponsor Protocol Number: FIBHGM-ECNC003-2021 Start Date*: 2023-06-01
    Sponsor Name:Fundación para la Investigación Biomédica del Hospital Gregorio Marañón
    Full Title: PHASE I/IIa OPEN CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF ALLOGENIC ADMINISTRATION OF TREG CELLS OBTAINED FROM THYMAL TISSUE (thyTreg) IN THE CONTROL OF IMMUNOLOGICAL HYPERACTIVATION ...
    Medical condition: immune hyperactivation in COVID-19 patients
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-004953-26 Sponsor Protocol Number: BHS-TC13 Start Date*: 2016-03-11
    Sponsor Name:Ghent University Hospital
    Full Title: CMV specific T cell therapy for the treatment of relapsing or therapy refractory CMV infection after allogeneic stem cell transplantation with a CMV-positive donor.
    Medical condition: CMV specific T cell therapy for the treatment of relapsing or therapy refractory CMV infection after allogeneic stem cell transplantation with a CMV-positive donor.
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-005247-78 Sponsor Protocol Number: OB003 Start Date*: 2022-01-19
    Sponsor Name:Oxygen Biotech s.r.o.
    Full Title: A 2-Part, Open-label, Non-randomized (Part A) and Randomized, Double-blinded, Placebo-controlled (Part B) multicentric, international study with adaptive design to evaluate safety and tolerability ...
    Medical condition: COVID-19 patients suffering from moderate to severe pneumonia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10035664 Pneumonia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2020-001254-22 Sponsor Protocol Number: SARPAC Start Date*: 2020-03-24
    Sponsor Name:University Hospital Ghent
    Full Title: A prospective, randomized, open-label, interventional study to investigate the efficacy of sargramostim (Leukine®) in improving oxygenation and short- and long-term outcome of COVID-19 patients wit...
    Medical condition: Acute hypoxic respiratory failure of COVID-19 patients
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10074615 Hypoxic respiratory failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2020-001807-18 Sponsor Protocol Number: TD-0903-0188 Start Date*: 2020-05-18
    Sponsor Name:Theravance Biopharma Ireland Limited
    Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-group, Multi-center Study of an Inhaled Pan-Janus Kinase Inhibitor, TD-0903, to Treat Symptomatic Acute Lung Injury Associated with...
    Medical condition: Acute lung injury associated with COVID-19
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004855 10047468 Viral lower respiratory tract infections HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) RO (Completed) FI (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jul 05 19:07:54 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA